Breakthrough T1D And Mattel Release First-Ever Barbie With Type 1 Diabetes via @forbes forbes.com/sites/gabbysha…

There is a new boss in town and she is smart, stylish, and deserves your respect and attention nbcnews.com/nightly-news/v…

The SURMOUNT-MMO trial is underway to test if #tirzepatide can reduce heart attacks, strokes, heart failure, and death in adults with obesity. This global study will enroll ~15,000 people at risk for cardiovascular events and is the first trial to see if an incretin medication

On the latest episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, BC-ADM, CDCES and @Natalie_Bellini discussed 3 of the top trials presented at the 85th annual meeting of the American Diabetes Association in Chicago, Illinois. Watch now: hcplive.com/view/diabetes-…

On the latest episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, BC-ADM, CDCES and @Natalie_Bellini discussed 3 of the top trials presented at the 85th annual meeting of the American Diabetes Association in Chicago, Illinois. Watch now: hubs.li/Q03xnbXb0

The Evolving Landscape of Insulin Delivery in Diabetes Management drugtopics.com/view/the-evolv… via @drugtopics

Top line results of the SURPASS-CVOT were announced! Tirzepatide went head to head vs dulaglutide and found to have less CV events including 16% lower rate of all cause death!

Exploring Reasons for the Underdiagnosis of Hypercortisolism drugtopics.com/view/exploring… via @drugtopics

Exploring Reasons for the Underdiagnosis of Hypercortisolism drugtopics.com/view/exploring… via @drugtopics

Just got back from #ADCES25! We’re discussing our biggest take-aways—early screening, evolving strategies for T1D management, and the role of TZIELD. Please see full Important Safety Information throughout this video, and Prescribing Information here: bit.ly/3IbU9Xn.

Just back from #ADCES25, and I’m truly inspired by the incredible progress happening in early-stage type 1 diabetes (T1D) care! A major highlight was the growing focus on identifying type 1 diabetes in its earliest stages—before symptoms begin. [1] Detecting risk earlier can

The new metabolic medicines #T2D #obesity and #inflammation cell.com/trends/endocri…

We hope to see you in Sunny San Diego Oct 22-23rd. Our top reasons to attend. You can register here: diabetesedstore.net/collections/li… Diabetes Education

Semaglutide is now approved for metabolic dysfunction-associated steatohepatitis

Original Article: Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2 phase 3a trial) nej.md/4ehQwLk Editorial: Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care nej.md/4ljVSHQ #Endocrinology

Dr. Viral Shah teaching how to optimize AID settings. Indiana university diabetes tech certificate course!

What does the approval of semaglutide for MASH mean for the more than 6% of US adults with the liver disease? Get the scoop in the latest #DiabetesDialogue with @DianaMisaacs and @Natalie_Bellini: hcplive.com/view/diabetes-… #Hepatology #MASH